Morepen FY26: Growth, Margin Pressure and the CDMO Pivot
Frequently Asked Questions
The presentation states Q4 FY26 revenue increased 22% year-on-year to Rs. 472 crore.
The presentation shows Q4 FY26 EBITDA of Rs. 32 crore versus Rs. 33 crore in Q4 FY25, with margin declining to 6.8% from 8.6%. PAT increased to Rs. 20 crore from Rs. 12 crore.
Standalone FY26 revenue was Rs. 1,703 crore (+8% YoY), EBITDA was Rs. 135 crore (-20% YoY), and PAT was Rs. 66 crore (-35% YoY), as shown in the annual financial momentum slide.
The presentation states a multi-year mandate of Rs. 823 crore was secured, audits and validation batches were completed, commercial production commenced, and a phased supply schedule was received with deliveries starting in the next few weeks.
The presentation states existing production base of about 500 KL, mid-term expansion to about 800 KL, and a long-term plan to about 1000 KL.
The board approved a second addendum to the Business Transfer Agreement with subsidiary Morepen Medipath Limited to revise the appointed date for the slump sale transfer to April 1, 2026; standalone notes state consideration of Rs. 19,710.12 lakhs subject to closing adjustments.
Yes. The board recommended a final dividend of Rs. 0.20 per equity share (face value Rs. 2) for FY26, subject to shareholder approval.
Did your stocks survive the war?
See what broke. See what stood.
Live Q1 Earnings Tracker